Michael J. Morris, MD: Can Lutetium-177–PSMA-617 Plus Standard of Care Improve Outcomes in Advanced Prostate Cancer?

Posted: Tuesday, June 15, 2021

Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center, discusses implications of the VISION trial findings, which suggest a targeted radioligand therapy appears to benefit men with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer. Should it prove beneficial beyond the clinical trial, the next question would be whether it would require specialized facilities.